FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312037214> ?p ?o ?g. }

• W4312037214 endingPage "13" @default.
• W4312037214 startingPage "12" @default.
• W4312037214 abstract "Background. Adrenocortical cancer (ACC) is a rare malignant endocrine tumor endowed with an aggressive biological potential and a poor prognosis. Surgical adrenalectomy remains the only radical treatment for local ACC. The overall 5-year survival rate of stages with local ACC varies from 56% to 96% and depends on the level of surgical training of a specialized center and the use of adjuvant therapy. Mitotan is the only approved chemotherapeutic agent for the adjuvant treatment of both the primary tumor and relapse and metastases. Aim. To evaluate the experience of mitotane successful use in a young patient with recurrent ACC using the experience of a large medical institution. Clinical observation . Patient R., 31 years old, is under dispensary observation for recurrent adrenocortical cancer of the left adrenal gland T1N0M0 stage 1, class 3. Progression from 2015, 2017, February 2019, April 2019, September 2020 (in the bed, MTS to the left kidney, MTS to the retroperitoneal tissue, MTS to the soft tissues of the lumbar region on the left, MTS to the lungs). Eradication of the tumor tissue was performed surgically, followed by morphological confirmation of the removed foci. For the first time, the diagnosis was established at the age of 23 during an examination for Itsenko-Cushing’s syndrome. Morphologically, the diagnosis of ACC was established after a histological examination of the tumor biopsy obtained by left-sided adrenalectomy (adrenocortical cancer, ki67 up to 20%). During a scheduled dispensary examination in September 2020, according to CT scan of the chest with contrast, two foci were identified in the right lung: in C1 — 10 * 15 mm, in C2 — 30 * 21 mm. By decision of the council (consisting of an oncologist-endocrinologist, a thoracic surgeon and a chemotherapist), a decision was made to prescribe mitotane with dose titration under the control of the level of mitotane in the blood until it reaches 14–20 ng/l, without morphological examination of the foci. Hypocorticism was corrected by the simultaneous use of hydrocortisone with mitotane at a dose of 20 mg per day under the control of ACTH levels. In X-ray evaluation by CT of the chest with a frequency of 3 months, the therapeutic effect in the form of a decrease in the size of the foci (RESIST1.1) occurred in the first 3 months. Mitotan was canceled in November 2021 after complete regression of tumor foci according to CT scan of the chest (pneumosclerosis areas 10*4 mm). Currently, the patient is receiving hormone replacement therapy with hydrocortisone 25 mg per day and is under dispensary observation. Conclusion. Clinical observation has demonstrated the successful use of mitotane in the treatment of metastatic adrenocortical cancer." @default.
• W4312037214 created "2023-01-04" @default.
• W4312037214 creator A5047841274 @default.
• W4312037214 creator A5049315077 @default.
• W4312037214 date "2022-12-14" @default.
• W4312037214 modified "2023-10-18" @default.
• W4312037214 title "Experience of mitotane successful in the treatment of metastatic adrenocortical cancer" @default.
• W4312037214 doi "https://doi.org/10.14341/serg12764" @default.
• W4312037214 hasPublicationYear "2022" @default.
• W4312037214 type Work @default.
• W4312037214 citedByCount "0" @default.
• W4312037214 crossrefType "journal-article" @default.
• W4312037214 hasAuthorship W4312037214A5047841274 @default.
• W4312037214 hasAuthorship W4312037214A5049315077 @default.
• W4312037214 hasBestOaLocation W43120372141 @default.
• W4312037214 hasConcept C121608353 @default.
• W4312037214 hasConcept C126322002 @default.
• W4312037214 hasConcept C126838900 @default.
• W4312037214 hasConcept C141071460 @default.
• W4312037214 hasConcept C143998085 @default.
• W4312037214 hasConcept C146357865 @default.
• W4312037214 hasConcept C151730666 @default.
• W4312037214 hasConcept C2775934546 @default.
• W4312037214 hasConcept C2776735609 @default.
• W4312037214 hasConcept C2780087391 @default.
• W4312037214 hasConcept C2781399356 @default.
• W4312037214 hasConcept C71924100 @default.
• W4312037214 hasConcept C86803240 @default.
• W4312037214 hasConceptScore W4312037214C121608353 @default.
• W4312037214 hasConceptScore W4312037214C126322002 @default.
• W4312037214 hasConceptScore W4312037214C126838900 @default.
• W4312037214 hasConceptScore W4312037214C141071460 @default.
• W4312037214 hasConceptScore W4312037214C143998085 @default.
• W4312037214 hasConceptScore W4312037214C146357865 @default.
• W4312037214 hasConceptScore W4312037214C151730666 @default.
• W4312037214 hasConceptScore W4312037214C2775934546 @default.
• W4312037214 hasConceptScore W4312037214C2776735609 @default.
• W4312037214 hasConceptScore W4312037214C2780087391 @default.
• W4312037214 hasConceptScore W4312037214C2781399356 @default.
• W4312037214 hasConceptScore W4312037214C71924100 @default.
• W4312037214 hasConceptScore W4312037214C86803240 @default.
• W4312037214 hasIssue "4" @default.
• W4312037214 hasLocation W43120372141 @default.
• W4312037214 hasOpenAccess W4312037214 @default.
• W4312037214 hasPrimaryLocation W43120372141 @default.
• W4312037214 hasRelatedWork W2018192686 @default.
• W4312037214 hasRelatedWork W2037978317 @default.
• W4312037214 hasRelatedWork W2412880734 @default.
• W4312037214 hasRelatedWork W2416979246 @default.
• W4312037214 hasRelatedWork W2802888094 @default.
• W4312037214 hasRelatedWork W3082301489 @default.
• W4312037214 hasRelatedWork W35534053 @default.
• W4312037214 hasRelatedWork W4380870709 @default.
• W4312037214 hasRelatedWork W55707150 @default.
• W4312037214 hasRelatedWork W91755469 @default.
• W4312037214 hasVolume "15" @default.
• W4312037214 isParatext "false" @default.
• W4312037214 isRetracted "false" @default.
• W4312037214 workType "article" @default.